- Saeed, A., Tabernero, J., Wang, G., Ma, X., Smith, R., & Hecht, J. (2024). Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study. Journal of Clinical Oncology, 42, TPS229-TPS229. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS229 (Meeting abstract)
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study
on 11 de novembre de 2024
with No hi ha comentaris
Deixa un comentari